Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: A phase III, randomized trial in adults aged ≥18 years

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Kieninger, Dorothee ^a   Sheldon, Eric ^b   Lin, Wen Yuan ^c   Yu, Chong Jen ^d   Bayas, Jose M ^e   Gabor, Julian J ^f   Esen, Meral ^f   Fernandez Roure, Jose Luis ^g   Narejos Perez, Silvia ^h   Alvarez Sanchez, Carmen ^h   Feng, Yang ⁱ   Claeys, Carine ⁱ   Peeters, Mathieu ⁱ   Innis, Bruce L ^j   Jain, Varsha ^j  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b MIAMI RESEARCH ASSOCIATES   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g Àrea Bàsica de Salut La Roca del Vallès   (Spain)

^h CAP de Centelles   (Spain)

ⁱ GSK   (Belgium)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

Non inferiority; Quadrivalent; Seasonal influenza; Superiority; Trivalent

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART ARREST; HEART DISEASE; HEART INFARCTION; HEMAGGLUTINATION INHIBITION TEST; HEPATIC COMA; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INTESTINE INFARCTION; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MYALGIA; PHASE 3 CLINICAL TRIAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; SHIVERING; SIDE EFFECT; SINUSITIS; SUDDEN DEATH; URINARY TRACT INFECTION; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84880343989     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-343     Document Type: Article

References (25)

1. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR Recomm Rep 2010, 59(RR-8):1-62.
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25(27):5086-5096. 10.1016/j.vaccine.2007.03.046, 17544181.
3. Li S, Leader S. Economic burden and absenteeism from influenza-like illness in healthy households with children (5-17 years) in the US. Respir Med 2007, 101(6):1244-1250. 10.1016/j.rmed.2006.10.022, 17156991.
4. Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin Infect Dis 2009, 48(3):292-298. 10.1086/595842, 19115970.
5. Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respi Viruses 2012, 6(2):142-152. e141-145.
6. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990, 175(1):59-68. 10.1016/0042-6822(90)90186-U, 2309452.
7. Centers for Disease Control and Prevention Seasonal influenza activity surveillance reports: 2000-2001 to 2010-2011 seasons http://www.cdc.gov/flu/weekly/pastreports.htm, Centers for Disease Control and Prevention.
8. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28(9):2149-2156. 10.1016/j.vaccine.2009.11.068, 20003926.
9. Tricco A, Chit A, Soobiah S, Hallett D, Meier G, Chen M, Tashkandi M, Bauch C, Loeb M. Effect of influenza vaccination against mismatched strains: a systematic review 2012, Vancouver, Canada: Canadian Immunization Conference.
10. United States Centers for Disease Control and Prevention Seasonal influenza activity surveillance reports: 2000-2001 to 2010-2011 seasons http://www.cdc.gov/flu/weekly/fluactivitysurv.htm, United States Centers for Disease Control and Prevention.
11. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30(11):1993-1998. 10.1016/j.vaccine.2011.12.098, 22226861.
12. World Health Organization Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season 2012, http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf, World Health Organization.
13. Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012, 31(7):745-751. 10.1097/INF.0b013e31825687b0, 22466322.
14. U.S. Food and Drug Administration FDA approves first quadrivalent vaccine to prevent seasonal influenza 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm, U.S. Food and Drug Administration.
15. Hehme N, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger R. Ten years of experience with the trivalent split-influenza vaccine, fluarix™. Clin Drug Invest 2002, 22(11):751-769.
16. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199(2):159-167. 10.1086/595861, 19086915.
17. Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009, 200(12):1861-1869. 10.1086/648406, 19909082.
18. Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, Jirincova H, Van Belle P, Jain V, Innis B, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009, 9(2):2. 2639595, 19149900.
19. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(2):179-186. 10.1001/jama.289.2.179, 12517228.
20. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012, 8(1):81-88. 3350141, 22252006.
21. Lee N, Choi KW, Chan PK, Hui DS, Lui GC, Wong BC, Wong RY, Sin WY, Hui WM, Ngai KL, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010, 65(6):510-515. 10.1136/thx.2009.130799, 20522848.
22. Aebi T, Weisser M, Bucher E, Hirsch HH, Marsch S, Siegemund M. Co-infection of influenza B and streptococci causing severe pneumonia and septic shock in healthy women. BMC Infect Dis 2010, 10:308. 10.1186/1471-2334-10-308, 2988048, 20979628.
23. Gaunt ER, Harvala H, McIntyre C, Templeton KE, Simmonds P. Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model. J Clin Virol 2011, 52(3):215-221. 10.1016/j.jcv.2011.07.017, 21880543.
24. US Food and Drug Administration. Guidance for Industry Clinical data needed to support the licensure of pandemic influenza vaccines 2007, http://www.fdagov/cber/gdlns/panfluvac.htm, US Food and Drug Administration. Guidance for Industry.
25. Camilloni B, Neri M, Lepri E, Basileo M, Sigismondi N, Puzelli S, Donatelli I, Iorio AM. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine 2012, 28(47):7536-7541.